STOCK TITAN

Perrigo to Release Third Quarter 2023 Financial Results on November 7, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Perrigo Company plc plans to issue its Q3 2023 financial results on November 7, 2023, and will host a conference call. The call will be available live via webcast or by phone. A taped replay of the call will also be available.
Positive
  • Perrigo Company plc will release its Q3 2023 financial results, which could positively affect investor sentiment and potentially lead to an increase in stock price.
Negative
  • None.

DUBLIN, Oct. 24, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2023 financial results on Tuesday, November 7, 2023, and will host a conference call beginning at 8:30 A.M. (EST).

The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-317-6003, International 412-317-6061, and reference ID # 0043209. A taped replay of the call will be available beginning at approximately 12:00 P.M. (EST) Tuesday, November 7, until midnight Tuesday, November 14, 2023. To listen to the replay, dial 877-344-7529, International 412-317-0088, and use access code 7630596.

About Perrigo 

Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com.

Forward-Looking Statements

This press release includes, and the matters discussed in Perrigo's upcoming earnings release will include certain "forward-looking statements" within the meaning of the Private Litigation Securities Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties, and other factors—many of which beyond the Company's control—that may cause the actual results, performance, or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2022.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-to-release-third-quarter-2023-financial-results-on-november-7-2023-301965953.html

SOURCE Perrigo Company plc

FAQ

When will Perrigo Company plc release its Q3 2023 financial results?

Perrigo Company plc plans to release its Q3 2023 financial results on November 7, 2023.

How can I access the conference call?

The conference call will be available live via webcast on the Perrigo website or by phone.

Will there be a replay of the conference call?

Yes, a taped replay of the conference call will be available for a limited time.

PERRIGO COMPANY PLC

NYSE:PRGO

PRGO Rankings

PRGO Latest News

PRGO Stock Data

4.44B
134.68M
0.31%
99.54%
2.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DUBLIN 2

About PRGO

perrigo company plc, a top five global over-the-counter (otc) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. from its beginnings in 1887 as a packager of generic home remedies, perrigo, headquartered in ireland, has grown to become the world's largest manufacturer of otc products and supplier of infant formulas for the store brand market. the company is also a leading provider of branded otc products, generic extended topical prescription products and receives royalties from multiple sclerosis drug tysabri®. perrigo provides “quality affordable healthcare products®” across a wide variety of product categories and geographies primarily in north america, europe, and australia, as well as other key markets including israel and china. visit perrigo online at (http://www.perrigo.com).